One of the worst cruelties of lethal cancer is the phenomenon called wasting, or cachexia , in which a patient seems literally to diminish in bodily terms as the cancer ravages one or more internal organs.

Today, a team at Cancer Research UK Cambridge Institute, led by Professor Douglas Fearon, M.D., of Cold Spring Harbor Laboratory in New York and a Distinguished Scholar of the Lustgarten Foundation, publishes in Cell Metabolism results of experiments showing that tumours interfere with the patient's ability to cope with wasting and may even impair their ability to respond to immunotherapy.

In mouse models of human pancreatic and colon cancer, the team traces cachexia to a molecular reprogramming of the liver induced by the tumour, the effect of which is to alter the liver's normal response to caloric deficiency.

As the caloric deficiency worsens and weight continues to decline, the body responds by releasing stress hormones.

The team found that these hormones, in turn, prevent the immune system from responding to the tumour.

Thus the new research helps explain two ways in which pancreatic and colon tumours have long vexed doctors attempting to treat them: these tumours themselves set in motion the process that results in wasting; and wasting, in turn, accounts for why immune therapy for such cancers has typically failed.

Providing massive caloric supplementation - what doctors call hyperalimentation - does not vanquish wasting; and immune therapy does not impair the tumor's ability to thrive.

The researchers in Cambridge, led by M.D.-Ph.D. student Thomas R. Flint and oncologist Tobias Janowitz, M.D., Ph.D., performed experiments demonstrating that in mouse models of pancreas and colon cancer, liver reprogramming begins during pre-cachexia, when wasting has just begun but is not yet manifest.

Signals broadcast by tumour cells induce the release of interleukin 6 (IL-6), a molecular beacon of the immune system called a cytokine, that normally helps induce an immune response.

IL-6, in turn, impairs the capacity of the liver to respond to caloric deprivation, which is already under way in pre-cachectic mice.

The team proposes this liver reprogramming is the result of IL-6 suppressing a gene-regulating protein, or transcription factor, called PPAR-alpha, which in turn suppresses a vital process in the liver called ketogenesis.

"Translated into human terms, this means that when a cancer patient loses his or her appetite and decides not to eat, the liver is not going to generate sufficient energy to compensate for the caloric loss," explains Dr. Fearon.

Often, cancer patients don't eat, Dr. Fearon clarifies, not because they are nauseous due to chemotherapy; rather, they feel full and simply lose their appetite.

Importantly, he adds, his team's discovery that the tumour is programming the liver not to make calories, which are essential for continued brain function, assures two things.

One is that wasting will continue; the other is that the body, massively releasing glucocorticoids, or stress hormones, will thereby short-circuit the immune system's ability to respond to the tumour.

It's a vicious circle that sadly ends in death.

The team's discovery not only sheds light on why conventional caloric supplementation fails to curtail cachexia in cancer patients.

It also helps to account for the failure of T-cell checkpoint targeted immunotherapies in pancreatic and colon cancers.

The tumour, in effect, is fooling the immune system into thinking the tumour is not a threat but rather just normal regenerating tissue.

The team tested several ways of addressing liver reprogramming in pre-cachectic mice.

Using a mouse model that recapitulates human pancreatic cancer, they administered an antibody that targets and inactivates IL-6; the same mice received massive caloric supplements via infusion.

According to Dr. Flint, "Our data suggest that successful reversal of cachexia in people may well depend on co-administration of anti-IL-6 with nutritional support."

The team also noted that their findings may have relevance in a wide range of IL-6-associated illnesses in which weight loss in observed.

These include sepsis, HIV, tuberculosis, chronic obstructive pulmonary disease, cardiac failure and rheumatoid arthritis.

Source: Cell Metabolism